takeaway
Pharmaceutical intermediates refer to some chemical raw materials or chemical products used in pharmaceutical synthesis process.
According to the industry, pharmaceutical intermediates industry, as an important field of fine chemical industry, will have a large development space in the future.

From the development history of China’s pharmaceutical intermediates industry, after nearly 30 years of development, pharmaceutical intermediates have developed from a small branch of the chemical industry into an emerging industry with an output value of billions of yuan, and the market competition is becoming increasingly fierce.

It is understood that in the early stage of the development of pharmaceutical intermediates industry, due to small investment and high rate of return, pharmaceutical intermediates enterprises spring up like bamboo shoots after a rain, especially in Zhejiang, Taizhou, Nanjing and other areas with favorable conditions for the development of pharmaceutical intermediates development is particularly rapid.

At present, as the change of medical market pattern, as well as the production of new drugs on the market is limited, the difficulty of pharmaceutical intermediates industry new product development is more and more big, the traditional product is becoming more and more fierce competition, pharmaceutical intermediates industry profits fell rapidly, and pharmaceutical intermediates become a have to think about the problem of how the development of an enterprise.

The industry believes that it may be possible to form its own competitive advantages from the aspects of technology, influence, transformation and so on, so as to stand out in the market.

In terms of technology, it mainly refers to improving technology and saving costs.
It is reported that pharmaceutical intermediates have long process route, many reaction steps, large amount of solvent, and great potential for technical improvement.

For example, lower value raw materials can be used instead of higher value raw materials, such as substitute bromine in the production of aminotaxime acid, ammonium thiocyanate instead of potassium thiocyanate (sodium) in the production, etc.

In addition, a single solvent can also be used to replace different solvents in the reaction process, and the alcohol generated by hydrolysis of ester products can be recovered.

In the aspect of influence, it is mainly to form its own characteristic products and improve the influence in the industry.
It is understood that because of China’s pharmaceutical intermediates industry, product homogenization competition is serious, if the enterprise can create their own superior products, will be able to occupy more advantages in the market.

In terms of transformation, at present, with the domestic environmental protection requirements becoming stricter, resources are inclined to high value-added industries, and with the increase of environmental protection costs, transformation has become a problem that pharmaceutical intermediates enterprises have to think about for sustainable development.

It is suggested that pharmaceutical intermediates enterprises extend the industrial chain upward and downstream, and transfer the main raw materials they use to their own production, which can further reduce the cost. Meanwhile, for some special raw materials, it can avoid the monopoly of key raw materials.

The industry says that moving down the road, where pharmaceutical intermediates are directly incorporated into APIs, can further increase the added value of products while selling them directly to pharmaceutical companies.
It is worth noting that the downstream investment is larger, while the production technology requirements are higher, and it is necessary to maintain a good relationship with the manufacturers that use the API.
On the whole, leading enterprises may gain more competitive advantages.

In addition, research and development is of great significance to the intermediate industry. At present, the pharmaceutical intermediate industry in China generally pays little attention to research and development.
Therefore, in the environment of constantly improving technical requirements, efficient R & D enterprises with strong R & D strength will come to the fore, while small and medium-sized enterprises without R & D ability may be eliminated by the market. In the future, the industry concentration will further increase, and the middle and low end development stage will develop to a higher stage.

MIT –IVY Chemicals Industry with 4 factories for 19years， dyes  Intermediates & pharmaceutical intermediates &fine &specialty chemicals  .  TEL(WhatsApp）:008613805212761 Athena